^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis
Excerpt:
...Tumor tissue samples or blood are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R)....
Trial ID:
Source:
Title:
A phase Ⅰ/Ⅱ study of Almonertinib with Bevacizumab in the first-line treatment of EGFR-mutant non-squamous non-small cell lung cancer patients with brain metastases
Excerpt:
...EGFR mutation is positive; 5. ...
Trial ID:
More C2 evidence
Source:
Title:
Multi-Center Clinical Study on the Efficacy and Safety of Almonertinib Combined with Bevacizumab and Pemetrexed in the First-Line Treatment of EGFR-Mutant Lung Adenocarcinoma Patients with Brain Metastases
Excerpt:
...5) The tumour harbours one of the EGFR mutations (Ex19del, L858R, G719AG719CG719SL861Q). ...
Trial ID:
Source:
Title:
Aumolertinib combined with bevacizumab in the first-line treatment of advanced NSCLC patients with EGFR-sensitive mutations and malignant pleural effusion and/or malignant pericardial effusion: a phase I/II clinical study
Excerpt:
...For patients with recurrence and metastasis after surgery, the time from the last postoperative adjuvant chemotherapy should be >=4 weeks; radiotherapy: the time from the last chest radiotherapy should be more than 12 weeks; the time from other parts of the radiotherapy should be more than 2 weeks; the time from the last operation more than 4 weeks (Except for thoracic or pericardial drainage); thoracic or pericardial drainage: more than 2 weeks or longer from the date of drainage; 2.Patients with malignant pleural effusion or pericardial effusion (in principle, cytological examination should be performed, but even if there is no malignant cytological examination, patients with imaging and clinical evidence of malignant pleural effusion or malignant pericardial effusion can also be used According to this standard, it is deemed qualified); 3.EGFR mutation positive; 4.Patients can take drugs orally; 5.Have one or more measurable lesions in accordance with the RECIST 1.1 standard; 6.ECOG score 0~2 points; 7.Aged 18 to 75 years; 8.The main organs are functioning normally, that is, they meet the following standards: (1)The standard of blood routine examination should meet: 1)ANC>=1.5x10^9/L; 2)PLT>=100x10^9/L; 3)Hb>=100g/L; (No blood transfusion or blood products, no correction with G-CSF and other hematopoietic stimulating factors within 14 days) (2)The biochemical inspection must meet the following standards: 1)TBIL=50ml/min (Cockcroft-Gault formula). ...
Trial ID:
Less C2 evidence
Source:
Title:
EP08.02-038 - Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis
Published date:
07/12/2022
Excerpt:
NSCLC patients with EGFRm and BMs are recruited into this multicenter, prospective clinical trial. Patients received oral aumolertinib (110 mg QD) plus intravenous bevacizumab (7.5 mg/kg) and pemetrexed (500mg/m2) for 4 cycles in first-line treatment...Confirmed partial response (PR) were achieved in 8 patients and stable disease (SD) in 2 patients, the ORR was 80% and disease control rate (DCR) was 100%. 9 patients (90%) had intracranial response, of which 2 had complete response, 7 had PR and 1 had SD, the iORR was 90% and iDCR was 100%.
Secondary therapy:
pemetrexed
Source:
Title:
EP08.02-169 - Research of Aumolertinib Combined with Bevacizumab for Advanced NSCLC Lung Cancer with EGFR Sensitive Mutation
Published date:
07/12/2022
Excerpt:
Aumolertinib plus bevacizumab exhibited superior activity for advanced EGFR-mutated NS-NSCLC, especially for patients with BMs.
